Prevalence and characteristics of anemia in inflammatory bowel disease;Prevalencia y características de la anemia en la enfermedad inflamatoria intestinal

Gastroenterologia y Hepatologia

Volumn 32, Issue 9, 2009, Pages 591-599

  de la Morena López, Felipe ^a   Gisbert, Javier P ^b,c  

^a HOSPITAL INFANTA CRISTINA   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Anemia; Crohn's disease; Inflammatory bowel disease; Iron; Iron deficiency anemia; Ulcerative colitis

Indexed keywords

FERRIC HYDROXIDE SUCROSE; FERROUS SULFATE;

ADULT; ANEMIA; ARTICLE; CLINICAL FEATURE; CROHN DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENTERITIS; FEMALE; HOSPITAL ADMISSION; HUMAN; IRON DEFICIENCY ANEMIA; IRON INTAKE; IRON THERAPY; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREVALENCE; RETROSPECTIVE STUDY; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ANEMIA; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES;

EID: 70349276721     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1016/j.gastrohep.2009.05.002     Document Type: Article

References (39)

1. Gasche C. Anemia in IBD: The overlooked villain. Inflamm Bowel Dis 6 (2000) 142-150 discussion 151
2. Gasche C., Lomer M.C., Cavill I., and Weiss G. Iron, anaemia, and inflammatory bowel diseases. Gut 53 (2004) 1190-1197
3. Gisbert J.P., and Gomollon F. Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. Am J Gastroenterol 103 (2008) 1299-1307
4. Pizzi L.T., Weston C.M., Goldfarb N.I., Moretti D., Cobb N., Howell J.B., et al. Impact of chronic conditions on quality of life in patients with inflammatory bowel disease. Inflamm Bowel Dis 12 (2006) 47-52
5. Wells C.W., Lewis S., Barton J.R., and Corbett S. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis 12 (2006) 123-130
6. Kulnigg S., and Gasche C. Systematic review: Managing anaemia in Crohn's disease. Aliment Pharmacol Ther 24 (2006) 1507-1523
7. Cucino C., and Sonnenberg A. Cause of death in patients with inflammatory bowel disease. Inflamm Bowel Dis 7 (2001) 250-255
8. Goodnough L.T., and Nissenson A.R. Anemia and its clinical consequences in patients with chronic diseases. Am J Med 116 (2004) 1S-2S
9. Goddard A.F., McIntyre A.S., and Scott B.B. Guidelines for the management of iron deficiency anaemia. British Society of Gastroenterology. Gut 46 (2000) IV1-IV5
10. Wilson A., Reyes E., and Ofman J. Prevalence and outcomes of anemia in inflammatory bowel disease: A systematic review of the literature. Am J Med 116 (2004) 44S-49S
11. Lennard-Jones J.E. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 170 (1989) 2-6 iscussion 16-9
12. Freire W.B. Iron-deficiency anemia: PAHO/WHO strategies to fight it. Salud Publica Mex 40 (1998) 199-205
13. Truelove S.C., and Witts L.J. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 2 (1955) 1041-1048
14. Van Hees P.A., Van Elteren P.H., Van Lier H.J., and Van Tongeren J.H. An index of inflammatory activity in patients with Crohn's disease. Gut 21 (1980) 279-286
15. Ganzoni A.M. Intravenous iron-dextran: Therapeutic and experimental possibilities. Schweiz Med Wochenschr 100 (1970) 301-303
16. Silverstein S.B., and Rodgers G.M. Parenteral iron therapy options. Am J Hematol 76 (2004) 74-78
17. Allen L.H. Iron supplements: Scientific issues concerning efficacy and implications for research and programs. J Nutr 132 (2002) 813S-819S
18. Bodemar G., Kechagias S., Almer S., and Danielson B.G. Treatment of anaemia in inflammatory bowel disease with iron sucrose. Scand J Gastroenterol 39 (2004) 454-458
19. Vijverman A., Piront P., Belaiche J., and Louis E. Evolution of the prevalence and characteristics of anemia in inflammatory bowel diseases between 1993 and 2003. Acta Gastroenterol Belg 69 (2006) 1-4
20. Cronin C.C., and Shanahan F. Anemia in patients with chronic inflammatory bowel disease. Am J Gastroenterol 96 (2001) 2296-2298
21. Means Jr. R.T., and Krantz S.B. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 80 (1992) 1639-1647
22. Taffet S.L., and Das K.M. Sulfasalazine. Adverse effects and desensitization. Dig Dis Sci 28 (1983) 833-842
23. Anstey A., Lennard L., Mayou S.C., and Kirby J.D. Pancytopenia related to azathioprine--an enzyme deficiency caused by a common genetic polymorphism: A review. J R Soc Med 85 (1992) 752-756
24. Gisbert J.P., Luna M., Mate J., González-Guijarro L., Cara C., and Pajares J.M. Thiopurine methyltransferase activity and myelosuppression in inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Med Clin (Barc) 121 (2003) 1-5
25. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 102 (2003) 783-788
26. Pietrangelo A., Dierssen U., Valli L., Garuti C., Rump A., Corradini E., et al. STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo. Gastroenterology 132 (2007) 294-300
27. Semrin G., Fishman D.S., Bousvaros A., Zholudev A., Saunders A.C., Correia C.E., et al. Impaired intestinal iron absorption in Crohn's disease correlates with disease activity and markers of inflammation. Inflamm Bowel Dis 12 (2006) 1101-1106
28. Graziadei I., Gaggl S., Kaserbacher R., Braunsteiner H., and Vogel W. The acute-phase protein alpha 1-antitrypsin inhibits growth and proliferation of human early erythroid progenitor cells (burst-forming units-erythroid) and of human erythroleukemic cells (K562) in vitro by interfering with transferrin iron uptake. Blood 83 (1994) 260-268
29. Wang C.Q., Udupa K.B., and Lipschitz D.A. Interferon-gamma exerts its negative regulatory effect primarily on the earliest stages of murine erythroid progenitor cell development. J Cell Physiol 162 (1995) 134-138
30. Maciejewski J.P., Selleri C., Sato T., Cho H.J., Keefer L.K., Nathan C.F., et al. Nitric oxide suppression of human hematopoiesis in vitro. Contribution to inhibitory action of interferon-gamma and tumor necrosis factor-alpha. J Clin Invest 96 (1995) 1085-1092
31. Faquin W.C., Schneider T.J., and Goldberg M.A. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 79 (1992) 1987-1994
32. De Silva A.D., Mylonaki M., and Rampton D.S. Oral iron therapy in inflammatory bowel disease: Usage, tolerance, and efficacy. Inflamm Bowel Dis 9 (2003) 316-320
33. Domenech E., Manosa M., Masnou H., Navarro M., García-Planella E., Bernal I., et al. Infliximab for the treatment of chronic anemia in Crohn's disease. Am J Gastroenterol 100 (2005) 496
34. Gasche C., Waldhoer T., Feichtenschlager T., Male C., Mayer A., Mittermaier C., et al. Prediction of response to iron sucrose in inflammatory bowel disease-associated anemia. Am J Gastroenterol 96 (2001) 2382-2387
35. Ferguson B.J., Skikne B.S., Simpson K.M., Baynes R.D., and Cook J.D. Serum transferrin receptor distinguishes the anemia of chronic disease from iron deficiency anemia. J Lab Clin Med 119 (1992) 385-390
36. Thomson A.B., Brust R., Ali M.A., Mant M.J., and Valberg L.S. Iron deficiency in inflammatory bowel disease. Diagnostic efficacy of serum ferritin. Am J Dig Dis 23 (1978) 705-709
37. Guagnozzi D., Severi C., Ialongo P., Viscido A., Patrizi F., Testino G., et al. Ferritin as a simple indicator of iron deficiency in anemic IBD patients. Inflamm Bowel Dis 12 (2006) 150-151
38. Gisbert J.P., Bermejo F., Pajares R., Pérez-Calle J.L., Rodríguez M., Algaba A., et al. Oral and intravenous iron treatment in inflammatory bowel disease: Hematological response and quality of life improvement. Inflamm Bowel Dis (2009) (en prensa)
39. De la Morena F., and Gisbert J.P. Anemia and inflammatory bowel disease. Rev Esp Enferm Dig 100 (2008) 285-293